Intensive chemotherapy and hematopoietic stem cell transplantation in the treatment of metastatic breast cancer: Results of the French PEGASE 04 national program;Intensification therapeutique et autogreffe de cellules souches hematopoietiques (CSH) dans le traitement des cancers du sein metastatiques: Resultats du programme national Pegase 04

Hematology and Cell Therapy

Volumn 41, Issue 2, 1999, Pages 71-74

  Lotz, J P ^a,b,c   Cure H ^b,c   Janvier, M ^b,c   Morvan, F ^b,c   Legros, M ^b,c   Asselain, B ^b,c   Guillemot, M ^b   Roché, Henri ^b,c,d   Gisselbrecht, C ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b FNCLCC   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Breast cancer; High dose chemotherapy; Stem cells transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; MELPHALAN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ADULT; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; ARTICLE; AUTOTRANSPLANTATION; BREAST TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; REMISSION; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033110380     PISSN: 12693286     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00282-999-0071-1     Document Type: Conference Paper

References (29)

1. Flamm Honig S Hormonal therapy and chemotherapy (for metastatic disease), in Harris JR, Lippman ME, Morrow M, Hellman S (eds) (1996) Diseases of the Breast. Philadelphia, PA, Lippincott-Raven, pp 669-734
2. Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281-1288
3. Henderson IC, Hayes DF, Gelman R (1988) Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6: 1501-1515
4. Antman KH, Rowlings PA, Vaughan WP, et al (1997) High-dose Chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15: 1870-1879
5. Gratwohl A, Passweg J, Baldomero H (1998) for the European Group for Blood and Marrow Transplantation: Blood and marrow activity in Europe in 1996. Bone Marrow Transplant 22: 227-240
6. Rodenhuis S, Westermann A, Holtkamp MJ, et al (1996) Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14: 1473-1483
7. Ghalie R, Richman CR, Adler SS, et al (1994) Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol 12: 342-346
8. Ayash LJ, Wheeler C, Fairclough D, et al (1995) Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13: 2043-2049
9. Dillman RO, Barth NM, Nayak SK, et al (1996) High-dose chemotherapy with autologous stem cell rescue in breast cancer. Breast Cancer Res 37: 277-289
10. Basade WM, Gulati SC (1998) High-dose chemotherapy in metastatic breast cancer. The Lancet 351: 386-387
11. Llungman P, Bjorkstrand B, Fornander, et al (1998) High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer. Bone Marrow Transplant 22: 445-448
12. Broun ER, Sridhara R, Sledge GW, et al (1995) Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 13: 2050-2055
13. Bitran HD, Samuels B, Llein L, et al (1996) Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 17: 157-162
14. Ueno NT, Rondon G, Mirza NQ, et al (1998) Allogenic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16: 986-993
15. Gisselbrecht C, Extra JM, Lotz JP, et al (1994) Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation in metastatic breast cancer. Bone Marrow Transplant 18: 857-863
16. Bezwoda WR, Seymour L, Dansey RD (1995) High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13: 2483-2489
17. Peters WP, Jones RB, Vredenburgh J, et al (1996) A large prospective randomized trial of high dose combination alkylating agents (CPB) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 15: A149 (abstr)
18. Kaplan EL, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457-481
19. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
20. Miller AB, Hoogstraten B, Staquet M, Winckler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
21. Rahman ZU, Frye DK, Buzdar AU, et al (1997) Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15: 3171-3177
22. Dunphy FR, Spitzer G, Buzdar AU, et al (1990) Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8: 1207-1216
23. Dunphy FR, Spitzer G, Fornoff JE, et al (1994) Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 73: 2157-2167
24. Eddy DM (1992) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10: 657-670
25. Diel IJ, Kaufman M, Goerner R, et al (1992) Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastases. J Clin Oncol 10: 1534-1539
26. Ross A, Cooper BW, Lazarus HM, et al (1993) Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82: 2605-2610
27. Dattta YH, Adams PT, Drobyski WR, et al (1994) Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12: 475-482
28. Brugger W, Bross KJ, Glatt M, et al (1994) Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83: 636-640
29. Cooper BW, Moss TJ, Ross A, et al (1998) Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 16: 3509-3517